ES2180809T3 - Administracion sublingual y bucal de selegilina. - Google Patents

Administracion sublingual y bucal de selegilina.

Info

Publication number
ES2180809T3
ES2180809T3 ES96938783T ES96938783T ES2180809T3 ES 2180809 T3 ES2180809 T3 ES 2180809T3 ES 96938783 T ES96938783 T ES 96938783T ES 96938783 T ES96938783 T ES 96938783T ES 2180809 T3 ES2180809 T3 ES 2180809T3
Authority
ES
Spain
Prior art keywords
selegiline
conditions
diseases
sublingual
responsive diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96938783T
Other languages
English (en)
Other versions
ES2180809T5 (es
Inventor
Anthony R Disanto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset Pharmaceuticals Inc
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21725510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180809(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2180809T3 publication Critical patent/ES2180809T3/es
Publication of ES2180809T5 publication Critical patent/ES2180809T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA A PROCEDIMIENTOS MEJORADOS PARA TRATAR CIERTAS ENFERMEDADES O TRASTORNOS QUE RESPONDEN A LA SELEGILINA, Y DE FORMA MAS ESPECIFICA, A PROCEDIMIENTOS EN LOS CUALES SE ADMINISTRA SELEGILINA POR VIA BUCAL O SUBLINGUAL. LA SELEGILINA PUEDE UTILIZARSE COMO UNA BASE LIBRE O COMO UNA SAL DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLE. LAS ENFERMEDADES O TRASTORNOS QUE RESPONDEN A LA SELEGILINA INCLUYEN ENFERMEDADES Y TRASTORNOS DE DEGENERACION NEURONAL, TAL COMO LA ENFERMEDAD DE ALZHEIMER Y LAS LESIONES NEURONALES PRODUCIDAS POR HIPOXIA, ACCIDENTES CEREBROVASCULARES, ISQUEMIA Y TRAUMATISMOS, Y ENFERMEDADES Y TRASTORNOS QUE RESPONDEN A LA SELEGILINA DE RELACION DOPAMINERGICA, TAL COMO LA DEPRESION Y ADHD.
ES96938783T 1995-11-06 1996-11-05 Administracion de selegilina sublingual y bucal. Expired - Lifetime ES2180809T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US732595P 1995-11-06 1995-11-06
US7325P 1995-11-06

Publications (2)

Publication Number Publication Date
ES2180809T3 true ES2180809T3 (es) 2003-02-16
ES2180809T5 ES2180809T5 (es) 2005-06-16

Family

ID=21725510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96938783T Expired - Lifetime ES2180809T5 (es) 1995-11-06 1996-11-05 Administracion de selegilina sublingual y bucal.

Country Status (13)

Country Link
US (1) US6117912A (es)
EP (1) EP0866691B2 (es)
JP (1) JPH11504944A (es)
CN (1) CN1207675A (es)
AT (1) ATE219358T1 (es)
AU (1) AU707646B2 (es)
CA (1) CA2236368C (es)
DE (1) DE69621946T3 (es)
DK (1) DK0866691T4 (es)
ES (1) ES2180809T5 (es)
NO (1) NO317855B1 (es)
PT (1) PT866691E (es)
WO (1) WO1997017067A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
PL183266B1 (pl) † 1995-03-02 2002-06-28 Scherer Ltd R P Doustna kompozycja farmaceutyczna,sposób wytwarzania doustnej kompozycji farmaceutycznej oraz zastosowanie doustnej kompozycji farmaceutycznej
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
AU2002239464B2 (en) 2000-11-01 2007-01-04 Cognition Pharmaceuticals Llc Methods and compositions for regulating memory consolidation
US7619005B2 (en) 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
EP1743631A3 (en) * 2000-11-01 2009-11-18 Cognition Pharmaceuticals LLC Use of an amphetamine composition for regulating memory consolidation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
WO2003059336A1 (en) * 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
EP1708686B1 (en) * 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
DE602004031771D1 (de) * 2003-12-31 2011-04-21 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
WO2006091544A2 (en) * 2005-02-22 2006-08-31 Northwestern University Methods and compositions for modulating calcium channels
WO2007005879A2 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
CN103860503A (zh) * 2012-12-10 2014-06-18 天津市汉康医药生物技术有限公司 一种治疗帕金森病的缓释药物组合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE55245T1 (de) * 1986-04-16 1990-08-15 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4885154A (en) * 1988-03-01 1989-12-05 Alza Corporation Method for reducing sensitization or irritation in transdermal drug delivery and means therefor
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5151449A (en) * 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5192808A (en) * 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
PL183266B1 (pl) * 1995-03-02 2002-06-28 Scherer Ltd R P Doustna kompozycja farmaceutyczna,sposób wytwarzania doustnej kompozycji farmaceutycznej oraz zastosowanie doustnej kompozycji farmaceutycznej

Also Published As

Publication number Publication date
EP0866691A1 (en) 1998-09-30
NO982044D0 (no) 1998-05-05
JPH11504944A (ja) 1999-05-11
DK0866691T3 (da) 2002-10-14
AU7608096A (en) 1997-05-29
CN1207675A (zh) 1999-02-10
DE69621946D1 (de) 2002-07-25
CA2236368A1 (en) 1997-05-15
AU707646B2 (en) 1999-07-15
EP0866691B2 (en) 2005-01-26
NO317855B1 (no) 2004-12-20
EP0866691B1 (en) 2002-06-19
WO1997017067A1 (en) 1997-05-15
ES2180809T5 (es) 2005-06-16
NO982044L (no) 1998-07-02
ATE219358T1 (de) 2002-07-15
DE69621946T2 (de) 2003-01-30
CA2236368C (en) 2001-10-23
DK0866691T4 (da) 2005-06-06
PT866691E (pt) 2002-11-29
US6117912A (en) 2000-09-12
DE69621946T3 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
PT866691E (pt) Administracao sublingual e bucal de selegilina
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
SE9503924D0 (sv) Novel opioid peptides
KR960701049A (ko) 헤테로사이클릭 화합물, 이의 제조방법 및 이의 용도(Heterocyclic compounds and their preparation and use)
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
UA41879C2 (uk) Засіб для лікування мотонейронових захворювань
DE69006072D1 (de) Verfahren zur Herstellung von N-Methyl-3-(p-Trifluoromethyl-phenoxy)-3-phenyl-propylamin und ihre Salze.
ATE206916T1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
DK0573538T3 (da) Peptider til behandling
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
HUP0003174A2 (hu) 20(S)-Kamptotecin glikokonjugátumai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ATE371737T1 (de) Proteaseresistente flint-analoge
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
ES2074946A1 (es) Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
KR940011479A (ko) 시클로 펩티드
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
MY132436A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
DE69630876D1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie